Evidence map›Paper›PMID 28364271›Full record

ArticleMedical oncology (Northwood, London, England)2017

ALK rearrangement in specific subtypes of lung adenocarcinoma: immunophenotypic and morphological features.

Luciana Possidente, Matteo Landriscina, Giuseppe Patitucci, Ludovica Borgia, Vittoria Lalinga, Giulia Vita

Abstract read
PubMed Publisher
In one paragraph

Article in Medical oncology (Northwood, London, England), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Luciana PossidenteLaboratory of Clinical Research and Advanced Diagnostics, IRCCS-CROB, Referral Cancer Center of Basilicata, 85028, Rionero in Vulture, Italy. luciana.possidente@crob.it.
Matteo LandriscinaLaboratory of Preclinical and Translational Research, IRCCS, Referral Cancer Center of Basilicata, 85028, Rionero in Vulture, Italy.
Giuseppe PatitucciPathology Unit, IRCCS, Referral Cancer Center of Basilicata, 85028, Rionero in Vulture, Italy.
Ludovica BorgiaPathology Unit, IRCCS, Referral Cancer Center of Basilicata, 85028, Rionero in Vulture, Italy.
Vittoria LalingaPathology Unit, IRCCS, Referral Cancer Center of Basilicata, 85028, Rionero in Vulture, Italy.
Giulia VitaPathology Unit, IRCCS, Referral Cancer Center of Basilicata, 85028, Rionero in Vulture, Italy.
Istituti di Ricovero e Cura a Carattere Scientifico · ITCentro di Riferimento Oncologico della Basilicata · ITUniversity of Foggia · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lung adenocarcinomas are characterized by a variety of genetic and epigenetic changes that lead to activation of specific signaling pathways. This allowed the classification of lung adenocarcinomas according to genetic alterations and the clinical development of novel anticancer agents that affect the activity of specific oncoproteins. In such a context, chromosomal rearrangements that cause constitutive activation of ALK gene define a category of lung adenocarcinomas that is amenable to targeted therapy with ALK inhibitors. Thus, a major issue of current research is to define the morphological and immunophenotypic features of lung ALK-rearranged adenocarcinomas to improve the selection of tumors suitable for molecular genotyping. ALK status was determined, by immunohistochemistry and fluorescence in situ hybridization, in 94 surgically resected lung adenocarcinomas and correlated with histomorphological parameters. Indeed, ALK rearrangement was observed in 10/94 (11%) lung adenocarcinomas and enriched in tumors with a predominant mucinous (46%; p < 0.05) and solid (29%; p < 0.05) pattern. By contrast, it was lacking or sporadically observed in lung adenocarcinomas with predominant acinar, papillary or lepidic pattern. Moreover, the presence of signet-ring cells was predominantly observed in ALK-rearranged tumors (47%; p < 0.05). These data suggest that ALK rearrangement is associated with specific and distinct clinical-pathological characters compared to other genotypes. Thus, the knowledge of these characteristics can improve the diagnostic accuracy and lead to a better understanding of the behavior of ALK-rearranged NSCLC.

Indexed as

AdenocarcinomaAdenocarcinoma of LungAgedAged, 80 and overAnaplastic Lymphoma KinaseDNA-Binding ProteinsFemaleGene RearrangementHumansImmunophenotypingIn Situ Hybridization, FluorescenceLung NeoplasmsMaleMiddle AgedReceptor Protein-Tyrosine KinasesTranscription FactorsALK protein, humanAnaplastic Lymphoma KinaseDNA-Binding ProteinsReceptor Protein-Tyrosine KinasesTranscription FactorsTTF1 protein, humanALK rearrangementFISH analysisHistomorphological parametersNon-small cell lung adenocarcinomas

Identifiers

PMID28364271
OpenAlexW2601057169

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.